The FDA has reprimanded Bayer for the “attention-grabbing visuals” and “frequent scene changes” in ads for the company’s ...
Patient groups’ perceptions of drugmakers with large U.S. footprints have shifted in the past year as the businesses have ...
In GSK’s first quarter with Luke Miels as CEO, the company’s flagship shingles vaccine Shingrix set a new quarterly sales ...
Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...
As regulatory delays continue to plague Regeneron’s efforts to develop Eylea, sales for the eye disease medicine remain in ...
Teva’s overall performance topped Wall Street estimates for Q1, according to Bloomberg News, which also pointed out that the ...
As Ekterly nears the one-year anniversary of its FDA approval, Italy’s Chiesi Group is making moves to acquire the rare ...
Three years after AbbVie stood at the edge of a major patent cliff with the loss of exclusivity for immunology ...
As AstraZeneca braces for the impact of the U.S. “most favored nation” drug pricing policy, CEO Pascal Soriot suggests that a ...
Novartis CEO Vas Narasimhan says Europe needs a “complete rethink” of how it prices its drugs, warning that the entrance of ...
Novartis CEO Vas Narasimhan is doubling down on his $5 billion peak sales projection for Pluvicto, even as the company has ...
Earlier this year, when the FDA asked Amgen to pull its rare disease drug Tavneos from the market, the California drugmaker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results